The DOI matches its Crossref record.
THE EFFECT OF THE INTESTINAL POLYPEPTIDES, IRP AND GIP, ON INSULIN|RELEASE AND GLUCOSE TOLERANCE IN THE BABOON
Abstract
The recently isolated intestinal polypeptides, intestinal insulin releasing polypeptide (IRP) and gastric inhibitory polypeptide (GIP), have been shown to potentiate glucose stimulated insulin release in the baboon. The effect was similar to that seen in the rat and demonstrates that both peptides affect insulin release in a broad range of species. No effect on glucagon release was observed. The possibility that either IRP or GIP, or both, is involved in the alimentary augmentation of insulin release by oral glucose deserves consideration. It is now well recognized that intestinal hormones are concerned in the regulation of glucose homeostasis (McIntyre et al., 1964; Marks & Samols, 1970), but their absolute identity and relative importance is uncertain. Two recently isolated polypeptides, intestinal insulin releasing polypeptide (IRP) (Turner, 1972; Turner et al., 1973) and gastric inhibitory polypeptide (GIP) (Brown et al., 1969), have been shown to produce dramatic effects on the insulinaemic response to intravenous glucose in the rat (Turner et al., 1973; Dupré, 1973). In order to determine whether these effects are limited to the rat, or a general phenomenon, the ability of the two peptides to augment the insulin response to intravenous glucose was examined in the baboon, Papio papio. In view of the known suppressive effect of oral glucose on glucagon release, plasma glucagon levels were also measured.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
GIP has protective features on β-cell survival, and this has a synergistic effect with GLP-1 in healthy humans, but this mechanism is impaired in those with T2DM.
“It has protective features on the β-cells survival, and this has a synergistic effect with GLP-1 in healthy humans, but this mechanism is impaired in those with T2DM [21,22].”
From The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. (2024) · cites this paper as [21]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 9
- Bloom S.R., 1971, A specific and sensitive glucagon immunoassay, Diabetologia, 7, 472
- 10.1139/o71-122 · DOI
- 10.1113/jphysiol.1970.sp009155 · DOI
- 10.1139/y69-020 · DOI
- 10.1016/S0140-6736(64)90011-X · DOI · Paper page
- Marks V., 1970, Advances in Metabolic Disorders, 1
- 10.1016/S0016-5085(72)80144-6 · DOI
- Turner D.S.(1972)Intestinal factors and the control of insulin release.Ph.D. thesis University of London.
- 10.1210/endo-93-6-1323 · DOI
Cited by
Sorted by citations
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
Jakubowska, A., Roux, C. W. L., & Viljoen, A. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1942 · Cited by 45
The power of three: Retatrutide’s role in modern obesity and diabetes therapy
Abdul-Rahman, T., Roy, P., Ahmed, F. K., Mueller-Gomez, J. L., Sarkar, S., Garg, N., Femi-Lawal, V. O., Wireko, A. A., Thaalibi, H. I., Hashmi, M. U., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177095 · Cited by 27
Metadata
- Authors
- TURNER, D. S., ETHERIDGE, L., JONES, J., MARKS, V., MELDRUM, B., BLOOM, S. R., & BROWN, J. C.
- Affiliations
- University of Surrey (GB)
- University of British Columbia (CA)
- Corresponding author
- TURNER, D. S.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 1974-10
- Volume
- 3
- Issue
- 4
- Pages
- 489-493
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2049533855
- Cited by
- 25
- References
- 0
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 3 · 2021: 1 · 2020: 1 · 2019: 1 · 2016: 1
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- glucose-dependent insulinotropic polypeptide, insulin secretion, glucose tolerance, oral glucose, glucagon, intestinal hormones, glucose homeostasis, baboons, primates
- MeSH terms
- Insulin Secretion, Animals, Female, Gastrointestinal Hormones, Glucagon, Glucose Tolerance Test, Insulin, Intestines, Male, Papio, Peptides, Stimulation, Chemical, Stomach
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review